Levocetirizin Beta

Levocetirizine Dihydrochloride, the active ingredient in Levocetirizin Beta, is a second‑generation H1 receptor antagonist presented as an oral tablet for oral use. It is employed to relieve symptoms of allergic rhinitis and chronic idiopathic urticaria in adults and children when appropriate.

GNH USA supplies Levocetirizin Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levocetirizine Dihydrochloride is used to manage allergic conditions by blocking peripheral H1 receptors. - Allergic rhinitis: reduces nasal congestion, sneezing, itching and watery discharge. - Seasonal allergic rhinitis: alleviates symptoms triggered by pollen or other seasonal allergens. - Chronic idiopathic urticaria: diminishes the frequency and severity of hives and associated itching.

Levocetirizin Beta is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Drowsiness: mild to moderate sleepiness, especially after the first dose. - Fatigue: a feeling of reduced energy or tiredness. - Dry mouth: decreased salivation leading to oral dryness. - Headache: mild to moderate cranial pain. - Nausea: occasional stomach upset. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat. - Anaphylaxis: severe, life‑threatening allergic reaction. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic enzyme elevation: abnormal liver function tests. - Cardiac arrhythmia: rare QT‑interval prolongation.

Before initiating therapy, consider patient‑specific factors and safety measures. - Renal function assessment: dose adjustment may be required in renal impairment. - Hepatic impairment: use with caution in patients with liver disease. - Sedation risk: avoid operating machinery or driving until individual response is known. - Hypersensitivity monitoring: discontinue if signs of allergic reaction appear. - Pregnancy and lactation: only use if benefits outweigh potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levocetirizin Beta may interact with other medicines that affect its metabolism or enhance sedation.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase levocetirizine plasma levels. - Concurrent sedating antihistamines: additive drowsiness. - Alcohol: potentiates central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Theophylline: possible increase in theophylline concentrations. - Certain antidepressants (e.g., fluoxetine): may modestly raise levocetirizine exposure.